Page 523 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

54. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of 69. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
symptom-onset-to-balloon time and door-to-balloon time with clopidogrel in patients with acute coronary syndromes. N Engl J
mortality in patients undergoing angioplasty for acute myocar- Med. 2007;357:2001-2015.
dial infarction. JAMA. 2000;283:2941-2497. 70. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to
55. Schroder R, Dissmann R, Bruggemann T, et al. Extent of early aspirin in 45,852 patients with acute myocardial infarction: ran-
ST segment elevation resolution: a simple but strong predictor domised placebo-controlled trial. Lancet. 2005;366:1607-1621.
of outcome in patients with acute myocardial infarction. J Am 71. Chew DP, Moliterno DJ. A critical appraisal of platelet
Coll Cardiol. 1994;24:384-391. glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol. 2000;36:2028-
56. Anderson RD, White HD, Ohman EM, et al. Predicting out- 2035.
come after thrombolysis in acute myocardial infarction accord- 72. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary
ing to ST-segment resolution at 90 minutes: a substudy of the clinical benefits of coronary-artery stenting and blockade of
GUSTO III trial. Am Heart J. 2002;144:81-88. platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet
57. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med.
outcome after widespread use of coronary-artery stenting in 1999;341:319-327.
Canada. N Engl J Med. 1999;341:1957-1965. 73. EPISTENT Investigators. Randomised placebo-controlled and
58. Stone GW, Brodie BR, Griffin JJ, et al. Clinical and angiographic balloon-angioplasty-controlled trial to assess safety of coronary
follow-up after primary stenting in acute myocardial infarction: stenting with use of platelet glycoprotein- IIb/IIIa blockade.
the Primary Angioplasty in Myocardial Infarction (PAMI) stent Lancet. 1998;352:87-92.
pilot trial. Circulation. 1999;99:1548-1554. 74. Montalescot G, Barragan P, Wittenberg O, et al. Platelet gly-
59. ISIS-2 (Second International Study of Infarct Survival) coprotein IIb/IIIa inhibition with coronary stenting for acute
Collaborative Group. Randomised trial of intravenous strep- myocardial infarction. N Engl J Med. 2001;344:1895-1903.
tokinase, oral aspirin, both, or neither among 17,187 cases 75. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty
of suspected acute myocardial infarction: ISIS-2. Lancet. with stenting, with or without abciximab, in acute myocardial
1988;2:349-360. infarction. N Engl J Med. 2002;346:957-966.
60. Montalescot G, Sideris G, Meuleman C, et al. A randomized 76. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with
comparison of high clopidogrel loading doses in patients acute ST-segment-elevation myocardial infarction undergo-
with non-ST-segment elevation acute coronary syndromes: the ing primary percutaneous coronary intervention after clopi-
ALBION (Assessment of the Best Loading Dose of Clopidogrel dogrel loading: a randomized double-blind trial. Circulation.
to Blunt Platelet Activation, Inflammation and Ongoing 2009;119:1933-1940.
Necrosis) trial. J Am Coll Cardiol. 2006;48:931-938. 77. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin
61. Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynam- during primary PCI in acute myocardial infarction. N Engl J
ics of clopidogrel. Semin Thromb Hemost. 1999;25(suppl 2):3-8. Med. 2008;358:2218-2230.
62. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopido- 78. Van’t Hof AW, Ten Berg J, Heestermans T, et al. Prehospital
grel to aspirin and fibrinolytic therapy for myocardial infarction initiation of tirofiban in patients with ST-elevation myocardial
with ST-segment elevation. N Engl J Med. 2005;352:1179-1189. infarction undergoing primary angioplasty (On-TIME 2): a
63. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopido- multicentre, double- blind, randomised controlled trial. Lancet.
grel pretreatment before percutaneous coronary intervention 2008;372:537-546.
in patients with ST-elevation myocardial infarction treated 79. Antman EM, Hand M, Armstrong PW, et al. 2007 focused
with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294: update of the ACC/AHA 2004 guidelines for the manage-
1224-1232. ment of patients with ST-elevation myocardial infarction: a
64. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability report of the American College of Cardiology/American Heart
in individual responsiveness to clopidogrel: clinical implica- Association Task Force on Practice Guidelines. J Am Coll
tions, management, and future perspectives. J Am Coll Cardiol. Cardiol. 2008;51:210-247.
2007;49:1505-1516. 80. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term
65. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic deter- efficacy of bivalirudin and provisional glycoprotein IIb/IIIa
minants of response to clopidogrel and cardiovascular events. blockade vs heparin and planned glycoprotein IIb/IIIa blockade
N Engl J Med. 2009;360:363-375. during percutaneous coronary revascularization: REPLACE-2
66. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose randomized trial. JAMA. 2004;292:696-703.
clopidogrel based on platelet function testing after percutane- 81. Mehran R, Brodie B, Cox DA, et al. The Harmonizing Outcomes
ous coronary intervention. The GRAVITAS randomized trial. with RevasculariZatiON and Stents in Acute Myocardial
JAMA. 2011;305:1097-1105. Infarction (HORIZONS-AMI) Trial: study design and rationale.
67. Michelson AD, Frelinger AL 3rd, Braunwald E, et al. Am Heart J. 2008;156:44-56.
Pharmacodynamic assessment of platelet inhibition by prasu- 82. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in
grel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. patients undergoing primary angioplasty for acute myocardial
2009;30:1753-1763. infarction (HORIZONS-AMI): 1-year results of a randomised
68. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of controlled trial. Lancet. 2009;374:1149-1159.
prasugrel and clopidogrel loading doses on platelet function: 83. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin ver-
magnitude of platelet inhibition is related to active metabolite sus unfractionated heparin with fibrinolysis for ST-elevation
formation. Am Heart J. 2007;153:e9-e16. myocardial infarction. N Engl J Med. 2006;354:1477-1488.

Section03-O-ref.indd 3 1/20/2015 7:10:23 AM